2018年美国临床肿瘤学会年会:乳腺癌研究最新进展  

Latest advances in breast cancer treatment reported in 2018 annual conference of American Society of Clinical Oncology

作　　者：邵志敏 刘引 Shao Zhimin;Liu Yin(Department of Breast Surgery,Shanghai Cancer Hospital,Fudan University,Shanghai 200032,China;Institute of Oncology,Shanghai Cancer Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院乳腺外科,上海200032 [2]复旦大学附属肿瘤医院肿瘤研究所,上海200032

出　　处：《中华乳腺病杂志（电子版）》2018年第6期324-328,392-394,共6页Chinese Journal of Breast Disease(Electronic Edition)

摘　　要：2018年的ASCO年会从化疗、内分泌治疗以及免疫治疗这些角度,向临床医师呈现了诸多乳腺癌治疗领域的最新进展。在化疗研究领域,学者们仍然在试图挑选人群豁免化疗,或者试图实现部分减负;在新型的化合物及化疗联合靶向治疗方面,学者们正在寻求更精准的治疗方法,试图做到有的放矢;在内分泌治疗领域,内分泌治疗联合靶向药物仍然是研究的热点;在免疫治疗方面,晚期乳腺癌的治疗已取得初步疗效,并且,学者们也试图在早期乳腺癌的治疗中寻找其应用价值。The annual conference of American Society of Clinical Oncology(ASCO)in 2018 showed us the latest advances in chemotherapy,endocrine therapy and immunotherapy for breast cancer.In the field of chemotherapy,there is still an attempt to select people for exemption from chemotherapy or to try to relieve the drug burden.In the development of new compound and in the combination of chemotherapy and targeted therapy,the researchers are looking for more precise and targeted regimens.With regards to endocrine therapy,traditional endocrine drug combined with targeted therapy is still a hot spot.Immunotherapy has been proved effective in metastatic breast cancer,and now researchers are trying to investigate the clinical value of immunotherapy in early breast cancer.

关 键 词：乳腺肿瘤 化学疗法 内分泌治疗 靶向治疗 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]